scholarly journals Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer

2021 ◽  
Vol 12 (5) ◽  
pp. 2203-2210
Author(s):  
Xiaorong Lai ◽  
Qiumei Dong ◽  
Fei Xu ◽  
Sipei Wu ◽  
Dongyang Yang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Characteristics

Tranlesionsynthesis and clinical characteristics of tumor aggression in sporadic colorectal cancer

2019 ◽  
Vol 45 (2) ◽  
pp. e117
Author(s):  
G. Laporte ◽  
N. Leguisamo ◽  
H. Castro e Glória ◽  
G. Montenegro ◽  
D. Azambuja ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Characteristics ◽  
Sporadic Colorectal Cancer

scholarly journals Development of an Immune Infiltration-Related Eight-Gene Prognostic Signature in Colorectal Cancer Microenvironment

2020 ◽  
Vol 2020 ◽  
pp. 1-43
Author(s):  
Beilei Wu ◽  
Lijun Tao ◽  
Daqing Yang ◽  
Wei Li ◽  
Hongbo Xu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Score ◽  
Immune Cells ◽  
Clinical Characteristics ◽  
Cox Regression ◽  
Roc Curves ◽  
Functional Enrichment ◽  
Cox Regression Analysis ◽  
Immune Genes ◽  
Score Model

Objective. Stromal cells and immune cells have important clinical significance in the microenvironment of colorectal cancer (CRC). This study is aimed at developing a CRC gene signature on the basis of stromal and immune scores. Methods. A cohort of CRC patients (n=433) were adopted from The Cancer Genome Atlas (TCGA) database. Stromal/immune scores were calculated by the ESTIMATE algorithm. Correlation between prognosis/clinical characteristics and stromal/immune scores was assessed. Differentially expressed stromal and immune genes were identified. Their potential functions were annotated by functional enrichment analysis. Cox regression analysis was used to develop an eight-gene risk score model. Its predictive efficacies for 3 years, 5 years, overall survival (OS), and progression-free survival interval (PFI) were evaluated using time-dependent receiver operating characteristic (ROC) curves. The correlation between the risk score and the infiltering levels of six immune cells was analyzed using TIMER. The risk score was validated using an independent dataset. Results. Immune score was in a significant association with prognosis and clinical characteristics of CRC. 736 upregulated and two downregulated stromal and immune genes were identified, which were mainly enriched into immune-related biological processes and pathways. An-eight gene prognostic risk score model was conducted, consisting of CCL22, CD36, CPA3, CPT1C, KCNE4, NFATC1, RASGRP2, and SLC2A3. High risk score indicated a poor prognosis of patients. The area under the ROC curves (AUC) s of the model for 3 years, 5 years, OS, and PFI were 0.71, 0.70, 0.73, and 0.66, respectively. Thus, the model possessed well performance for prediction of patients’ prognosis, which was confirmed by an external dataset. Moreover, the risk score was significantly correlated with immune cell infiltration. Conclusion. Our study conducted an immune-related prognostic risk score model, which could provide novel targets for immunotherapy of CRC.

BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis

2012 ◽  
Vol 55 (2) ◽  
pp. 128-133 ◽  
Author(s):  
Matthew F. Kalady ◽  
Kathryn L. DeJulius ◽  
Julian A. Sanchez ◽  
Awad Jarrar ◽  
Xiuli Liu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Characteristics ◽  
Braf Mutations ◽  
Worse Prognosis

Abstract 2364: Clinical characteristics and outcomes of colorectal cancer in the ColoCare Study: Differences by age of onset

2020 ◽  
Author(s):  
Caroline Himbert ◽  
Jane Figueiredo ◽  
Lyen Huang ◽  
Biljana Gigic ◽  
Courtney L. Scaife ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Characteristics ◽  
Age Of Onset

Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3592-3592
Author(s):  
Gargi Surendra Patel ◽  
Shahid Ullah ◽  
Carol Beeke ◽  
Paul Hakendorf ◽  
Rob Padbury ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Body Mass Index ◽  
Overall Survival ◽  
Clinical Characteristics ◽  
Independent Predictor ◽  
Retrospective Data ◽  
Insulin Dependent ◽  
Baseline Characteristics ◽  
Metastatic Sites ◽  
The Relationship

3592 Background: Preclinical data suggest that adiposity activates pro-inflammatory and insulin-dependent pathways which may lead to resistance to TT, e.g., bevacizumab (Bev) or cetuximab (Cet). Only two retrospective trials have studied the relationship between BMI and outcome for mCRC pts who received TT, with conflicting results. Our aim was to compare OS across BMI groups for mCRC pts treated with TT. Methods: Retrospective data, pertaining to clinical characteristics and outcome, were obtained from the South Australian Registry for mCRC from Feb 2006-Oct 2012. The BMI at first treatment was grouped as Normal (N) = 18.5- <25, Overweight (OW) = 25- <30, Obese I(Ob1) = 30- <35, Obese II (Ob2)≥35. Results: Of 1,174 pts, 39% were OW, 15% Ob1 and 7% Ob2. 352 pts received chemo+TT (Bev, Cet, panitumumab (Pan) and/or regorafenib) and 814 chemo alone. Baseline characteristics were similar across all BMI groups except for type of mCRC: N pts were more likely than obese pts to have synchronous CRC (77.9% vs 56-69.7% for obese). On adjustment for age, sex, synchronous disease, metastatic sites, number of lines of chemo and TT, median OS was longer for N versus OW or Ob1 pts with chemo+TT (35.4 vs 24.9 or 22.7 mons, Table) with no difference in OS for chemo alone. Only N gp pts had an improvement in OS on the addition of TT to chemo. On breakdown by type of TT, OW and Ob1 pts had a poorer outcome with Bev but not with EGFR TT. Conclusions: The BMI is an independent predictor for a poorer outcome for OW and OB1 pts with chemo+TT, specifically for pts receiving Bev. The OW and OB1 patients may be a target group for lifestyle and nutrition advice to improve OS with TT. Prospective studies are required to validate this finding. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document